Vectorite Biomedical

Vectorite Biomedical Equity Growth

The Year-over-Year Equity Growth of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 24.55 %. In the previous year, Year-over-Year Equity Growth was -9.59 % — a change of -356.02% (higher).

Equity Growth

24.55 %

YoY

-356.02%

Last updated:

Year-over-Year Equity Growth of Vectorite Biomedical is 2025 24.55 % . Year-over-Year Equity Growth of Vectorite Biomedical was 2024 -9.59 % . It decreases by -356.02% higher compared to the previous year.

The Vectorite Biomedical Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-7.26 TWD
Jan 1, 2019
-14.77 TWD
Jan 1, 2020
20.60 TWD
Jan 1, 2021
35.37 TWD
Jan 1, 2022
-5.49 TWD
Jan 1, 2023
-2.37 TWD
Jan 1, 2024
-9.59 TWD
Jan 1, 2025
24.55 TWD
The Vectorite Biomedical Equity Growth history
YEAREquity GrowthYoY
24.55 %-356.02%
-9.59 %+304.29%
-2.37 %-56.79%
-5.49 %-115.52%
35.37 %+71.71%
20.60 %-239.49%
-14.77 %+103.50%
-7.26 %-638.49%
1.35 %-108.57%
-15.72 %+22.79%
-12.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Year-over-Year Equity Growth of Vectorite Biomedical is 24.55 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Vectorite Biomedical

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Vectorite Biomedical